Thymomas are tumors arising from the epithelial cells of the thymus, the organ behind the breastbone where immune cells called T lymphocytes mature. In goats, the thymus has paired cranial and cervical lobes plus a single thoracic lobe, and tumors can develop in the cranial mediastinum, the space between the lungs, or in the ventral neck region. Post-mortem surveys suggest thymomas make up roughly ten percent of all tumors in goats, and dairy breeds such as Nigerian Dwarf and Saanen may carry an even higher prevalence, with one classic study reporting rates as high as twenty-five percent. Despite how common they appear to be at necropsy, almost nothing has been published about actually treating them.

The goat arrived at the University of Florida Large Animal Hospital after several days of lethargy, fever, and reduced appetite. On examination she was febrile at 106.2 degrees Fahrenheit, with rapid heart and respiratory rates, hyperemic mucous membranes, poor rumen contractions, and a heart murmur. Bloodwork revealed elevated fibrinogen and creatine kinase, low protein and calcium, and abnormalities on venous blood gas. A point-of-care thoracic ultrasound uncovered the likely culprit: a mass in the cranial mediastinum, alongside B-line artifacts and small areas of consolidation in the front of the chest that pointed to pneumonia.

A computed tomography scan performed under general anesthesia characterized the mass in detail. It measured 8.6 by 6.5 by 6 centimeters, appeared heterogeneous in soft tissue and fluid attenuation, and enhanced strongly with contrast. The tumor was displacing the cranial vena cava caudodorsally, pushing the heart backward, and compressing the cranial lung lobes, but there was no vascular invasion. Ultrasound-guided fine-needle aspiration yielded lymphoid tissue with poorly preserved epithelial cell aggregates and occasional mast cells, findings most consistent with a neoplasm of thymic origin, suspected to be a thymoma. The team also identified patterns consistent with aspiration or chronic bronchopneumonia and treated the goat empirically with florfenicol.

Treatment options were weighed carefully with the owner. Surgical excision was declined because of the substantial risk of intraoperative hemorrhage, a complication that has proven fatal in the only two goats previously reported to undergo thoracic surgery for mediastinal thymoma. Radiation therapy was offered instead, with candid discussion of acute risks including pneumonitis, esophagitis, tracheitis, and myocarditis, and late risks such as cardiomyopathy, arrhythmia, and lung fibrosis. The owner elected a palliative-intent protocol of four weekly fractions of 8 Gy, totaling 32 Gy, a schedule chosen to reduce costs and minimize the number of hospital visits and anesthetic episodes.

The technical execution of the plan illustrates how far veterinary radiation oncology has come. The goat was positioned in sternal recumbency in a vacuum-sealed cushion for a planning CT scan. The contrast-enhancing mass was contoured as the gross tumor volume, expanded uniformly by 2 millimeters to create the planning target volume. Because thymomas typically move little with respiration, no internal target volume was used, and the small margin prioritized sparing nearby organs at risk: the lungs, heart, esophagus, trachea, and spinal cord. An inverse-planned intensity-modulated plan with eight coplanar isocentric beams was generated on the Eclipse planning system, normalized so that 95 percent of the target received the full prescription dose, with only 5.6 percent of lung volume receiving 20 Gy or more.

Quality assurance was rigorous. The plan was verified with a two-dimensional diode array, requiring at least 95 percent of measured points to agree with the calculated fluence at a 3 percent and 3 millimeter criterion. Treatment was delivered with 6 MV photons from a Varian Edge linear accelerator equipped with a 120-leaf multileaf collimator, and cone-beam CT scans taken before each session confirmed accurate positioning. Each fraction required general anesthesia, induced with propofol after butorphanol and midazolam premedication and maintained on isoflurane, with no complications. By the fourth fraction, the cone-beam CT already showed the tumor shrinking by roughly 5 millimeters in every dimension, and the goat’s appetite had returned to normal while her heart murmur had quieted.

The response endured. A recheck CT scan four months after treatment, performed during an unrelated emergency visit for fever and lethargy, showed the mass had shrunk to 6 by 4.6 by 5.2 centimeters, a 30 percent reduction that meets the formal definition of a partial response under Veterinary Cooperative Oncology Group RECIST criteria. The pulmonary changes seen before treatment had nearly resolved. A scan at ten months confirmed a persistent partial response, though it also revealed mild progression of lower airway inflammation and bronchopneumonia that the authors could not rule out as a low-grade late radiation effect or unrelated chronic bronchitis. Twenty months out, the owner reported only occasional mild coughing, and the goat was still alive at the time of manuscript submission, roughly 1,230 days after treatment began.

The result carries weight because the comparative literature is so thin. Only one previous goat with a cranial mediastinal thymoma had been treated with radiation, receiving 32 Gy in 4 Gy fractions every other day, with tumor regression noted by the sixth fraction and survival of at least 1.5 years. In dogs and cats, surgery remains the treatment of choice for thymoma, though perioperative mortality approaches 20 percent, and radiation produces overall response rates of 33 to 75 percent with median survival times of 5 to 8 months in dogs and 24 months in cats. Because metastasis is rarely seen in caprine thymoma, local control is the central therapeutic goal in goats as well, making radiation an attractive alternative when thoracic surgery is too risky or unavailable.

The authors acknowledge limitations, most notably that the diagnosis rested on cytology rather than the histopathology required for definitive confirmation of thymoma. They also note that the link between the goat’s pneumonia and the tumor is uncertain; in dogs, thymoma-associated megaesophagus drives aspiration pneumonia, but myasthenia gravis appears far less common in goats, and no megaesophagus was seen on CT. Still, the message is clear. As goats increasingly live as companion animals rather than production livestock, cancer care becomes a relevant expectation for their owners, and this case demonstrates that modern, image-guided, hypofractionated radiation therapy is technically feasible in goats, was well tolerated, and can produce objective, durable tumor shrinkage. Larger cohorts will be needed before firm recommendations can be made, but for pet goats facing inoperable mediastinal thymoma, radiation therapy now stands as a legitimate option to discuss.

Subject of Research: Palliative hypofractionated image-guided intensity-modulated radiation therapy for a cranial mediastinal thymoma in a Nigerian Dwarf goat

Article Title: Image-guided intensity-modulated radiation therapy for a mediastinal thymoma in a Nigerian Dwarf goat: a case report

Article References: Argenti, T., Jodzio, D., Hancock, K., Darby, S., Luethy, D., Gilor, S., Gutti, J., & Takada, M. (2026). Image-guided intensity-modulated radiation therapy for a mediastinal thymoma in a Nigerian Dwarf goat: a case report. Veterinary Oncology, 3(1), Article 4. https://doi.org/10.1186/s44356-026-00055-6

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00055-6

Keywords: thymoma, goat, radiation therapy, IMRT, veterinary oncology, Nigerian Dwarf goat, mediastinal mass, hypofractionated radiation, computed tomography, palliative care, caprine neoplasia, partial response

The study, led by Ashraf Nadeem, Yunfan Yang, Xinyan Li, and Kun Li of the Department of Hepatobiliary and Pancreatic Surgery at Zhongnan Hospital of Wuhan University, employed a frequentist network meta-analysis, a statistical framework that pools both direct comparisons and indirect evidence across a connected web of randomized trials. Because most adjuvant therapies for liver cancer have been tested only against observation or placebo rather than against each other, conventional pairwise meta-analysis cannot rank them. The network approach uses a shared common comparator—in this case, observation or placebo—as a statistical anchor, allowing the relative performance of treatments that have never faced each other in a trial to be estimated within a single model. Treatments were ranked using P-scores, which express the probability that one intervention outperforms another under the network model.

The evidence base was assembled through an exhaustive search of MEDLINE, Embase, CENTRAL, Web of Science, Scopus, regional databases, clinical trial registries, and conference proceedings covering trials published between January 2000 and December 2025. The investigators deliberately restricted their network to trials conducted exclusively in patients undergoing hepatic resection, excluding mixed populations that also included ablation or transplantation, in order to preserve clinical coherence and strengthen the transitivity assumption on which indirect comparisons depend. The review was prospectively registered in PROSPERO and reported according to the PRISMA 2020 statement and its network meta-analysis extension, with risk of bias assessed using the Cochrane Risk of Bias 2 tool.

The headline finding concerns overall survival. Three internal radiation and brachytherapy approaches dominated the survival hierarchy. Adjuvant iodine-125 brachytherapy showed the largest reduction in the hazard of death compared with observation, with a hazard ratio of 0.36 (95 percent confidence interval 0.17 to 0.78), followed by intensity-modulated radiation therapy, or IMRT, at a hazard ratio of 0.44 (0.23 to 0.86), and iodine-131-labeled metuximab, a radiolabeled antibody targeting HAb18G/CD147 on tumor cells, at 0.46 (0.28 to 0.77). In probabilistic terms, iodine-125 brachytherapy carried the highest P-score for overall survival at 0.86, ahead of IMRT at 0.78 and iodine-131-metuximab at 0.77. Conventional transarterial chemoembolization, long a mainstay of postoperative consolidation, retained activity with a hazard ratio of 0.71 (0.55 to 0.92) but was generally outperformed by the precision radiotherapy approaches.

The picture shifted when the outcome was recurrence-free survival, the primary endpoint of most adjuvant trials and typically the earliest signal of treatment failure. Here, the autologous formalin-fixed tumor vaccine, or AFTV, an immunotherapy prepared from a patient’s own resected tumor tissue, ranked first with a P-score of 0.92, followed by a combination of the traditional medicine Cidan capsule with transarterial chemoembolization at 0.90, iodine-125 brachytherapy at 0.84, and IMRT at 0.80. The divergence between the two hierarchies is not contradictory, the authors argue, but reflects differences in endpoint maturity and mechanism: recurrence events accrue earlier than deaths, and some strategies may suppress relapse long before any difference in survival fully matures.

The mechanistic reasoning behind these rankings is instructive. Early postoperative recurrence in hepatocellular carcinoma is frequently driven by microscopic residual disease, narrow resection margins, microvascular invasion, and venous dissemination—processes that concentrate relapse risk around the surgical bed and regional vascular pathways. IMRT is conceptually well suited to sterilizing this presumed microscopic disease in the postoperative field, whereas transarterial chemoembolization targets hypervascular visible tumor tissue through the arterial supply and is a less precise fit for the minimal residual disease setting. Meanwhile, the immune-based strategies operate systemically. Hepatocellular carcinoma typically arises in a chronically inflamed, immunologically dysregulated liver characterized by T-cell exhaustion and immune escape, and checkpoint inhibition with agents such as the PD-1 inhibitor sintilimab—which demonstrated a favorable benefit-risk profile in the network—aims to restore cytotoxic antitumor immunity against occult malignant clones throughout the remnant liver.

AFTV represents a different immunological logic altogether. Rather than amplifying pre-existing antitumor immunity, the autologous vaccine is designed to generate antigen-specific immune priming de novo, using formalin-fixed tumor tissue as a source of the full repertoire of tumor antigens in each individual patient. The authors note that this strategy is conceptually well matched to the adjuvant setting, where disease burden is minimal and immune containment is more achievable than in advanced disease. They are careful, however, to frame the finding as hypothesis-generating rather than definitive: the AFTV ranking rests on a single small phase II trial, mature overall survival data are lacking, and personalized vaccine platforms face practical challenges around standardization, scalability, and reproducibility across centers.

Safety signals across the 28 trials were reassuring. Grade 3 or higher adverse events were reported infrequently. Immune-related hepatitis of grade 3 occurred in 2 to 5 percent of patients receiving sintilimab, with no treatment-related deaths. Radiation-induced liver disease of grade 3 or worse was rare, affecting fewer than 1 percent of Child-Pugh A patients treated with IMRT. Post-embolization syndrome affected 5 to 10 percent of patients undergoing transarterial chemoembolization, and no grade 3 or higher events were reported for AFTV. The analysis also revealed that the strongest efficacy signals frequently came from clinically enriched high-risk populations: the sintilimab trial enrolled a cohort with 100 percent pathological microvascular invasion, the IMRT trial enrolled patients with 100 percent portal vein tumor thrombus, and the AFTV trial arose from a population with very high hepatitis B prevalence—features that matter for generalizability, since most included patients had hepatitis B virus-related disease and preserved liver function.

The authors are candid about the limitations of their work. The evidence network was largely star-shaped, with observation as the dominant comparator, meaning most comparisons between active treatments were estimated indirectly. Because the network contained no closed loops, formal consistency testing was not possible, and coherence rests entirely on the transitivity assumption. Hepatitis B prevalence ranged from 36 to 100 percent and microvascular invasion rates from 0 to 100 percent across trials, and meta-regression was infeasible given the small number of trials per covariate category. Landmark mixed-modality trials such as IMbrave050, which showed that adjuvant atezolizumab plus bevacizumab can reduce recurrence risk in high-risk patients after resection or ablation, could not be included because resection-specific estimates were not extractable. Evolving salvage therapies over the 26-year study window may also have influenced survival endpoints in older trials.

Nevertheless, the analysis points toward a future in which postoperative management of liver cancer is risk-adapted and mechanism-based rather than empiric. Precision radiotherapy may be most rational when relapse risk is concentrated in the surgical bed or vascular territory, while immune-based therapy may better serve patients whose recurrence risk is diffuse or systemic. The authors emphasize that not every patient should automatically receive adjuvant treatment; the strongest case exists for those with clearly elevated risk, such as microvascular invasion or tumor multiplicity. Large active-comparator randomized trials, standardized treatment-initiation windows, and biomarker-informed selection will be needed before a definitive standard emerges. Until then, this synthesis provides the clearest comparative map yet of a therapeutic landscape long defined by uncertainty.

Subject of Research: Comparative effectiveness of postoperative adjuvant therapies for hepatocellular carcinoma after curative resection, evaluated by network meta-analysis of randomized controlled trials

Article Title: Comparative efficacy and safety of postoperative adjuvant therapies after curative resection for hepatocellular carcinoma: a network meta-analysis

Article References: Nadeem, A., Yang, Y., Li, X., & Li, K. (2026). Comparative efficacy and safety of postoperative adjuvant therapies after curative resection for hepatocellular carcinoma: a network meta-analysis. Clinical Cancer Bulletin, 5(1), Article 14. https://doi.org/10.1007/s44272-026-00066-2

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00066-2

Keywords: hepatocellular carcinoma, network meta-analysis, adjuvant therapy, liver resection, iodine-125 brachytherapy, IMRT, iodine-131 metuximab, recurrence-free survival, overall survival, immunotherapy, tumor vaccine, TACE